Oxygen Biotherapeutics, Inc. Share Price Nasdaq
Equities
US69207P2092
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.15M 485M |
---|---|---|---|---|---|
Net income 2024 * | -19M -1.5B | Net income 2025 * | -18M -1.42B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 13/07/21 | |
Director of Finance/CFO | 69 | 01-10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 14/01/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 03/04/14 |
June Almenoff
BRD | Director/Board Member | 67 | 24/02/21 |
Declan Doogan
BRD | Director/Board Member | 72 | 24/02/21 |
1st Jan change | Capi. | |
---|---|---|
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |